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Recent epidemiological studies suggest that 30% to 50% of patients with heart failure (HF)
have preserved left ventricular (LV) systolic function. These patients, often presumed to have
diastolic heart failure (DHF), appear to have lower short-term but similar long-term
mortality when compared to patients with HF and LV systolic dysfunction. Rates of recurrent
hospitalization and costs of care appear similar in the two groups of patients. Therefore, DHF
may contribute significantly to the burden of disease caused by HF. Exertional breathlessness,
the principal symptom of HF, has many causes, including obesity, pulmonary disease and
myocardial ischemia. A diagnosis of DHF by exclusion, based on symptoms in the absence
of important LV systolic dysfunction or major valve disease, is unsatisfactory. Unfortunately,
as yet, no reliable definition with which to make a positive diagnosis of DHF has been agreed
on, frequently rendering this diagnosis uncertain. Echocardiography has several limitations,
whereas hemodynamic confirmation of DHF by cardiac catheterization is potentially complex
and not practically feasible for many patients. Treatment of DHF remains empirical and
unsatifasctory because of the lack of large-scale randomized controlled trials in this area.
Currently, three large outcome studies on DHF are in progress along with other smaller trials.
These should start to provide some of the answers we need to diagnose and effectively treat
DHF. (J Am Coll Cardiol 2002;39:138–41) © 2002 by the American College of
Cardiology
A number of recent community-based epidemiological
studies of heart failure (HF) have suggested that 30% to
50% of cases of HF have preserved left ventricular (LV)
systolic function (1–3). It is often assumed that these cases
represent diastolic heart failure (DHF). If true, this suggests
that DHF contributes significantly to the huge burden of
disease caused by HF (4). However, although there has been
an intense focus on HF due to LV systolic dysfunction, with
considerable evolution in our understanding of the patho-
physiology and natural history of the disease and subse-
quently the development of new treatments (5–7), there has
been little parallel progress for DHF. Consequently, if the
epidemiological evidence is accurate, a large proportion of
the HF population is left with no proven, effective treat-
ment.
The incidence, prevalence and prognosis of DHF form a
contentious issue. The Framingham offspring study (1) and
the Olmsted County study (3) used a scoring system based
on symptoms and signs for the diagnosis of incident HF.
Echocardiograms did not form part of the diagnostic
criteria and were undertaken subsequently to document
ventricular function. Of the 123 Framingham offspring who
had a clinical diagnosis of HF, 73 underwent echocardiog-
raphy. Of these, 51% were found to have preserved LV
systolic function. The five-year mortality for these patients
was 68% compared to 82% for matched control subjects
without HF (p  0.0001) (1). Similarly, the Olmsted
County study (3) found that 43% of cases of incident HF
had preserved systolic function on echocardiography; both
DHF and systolic heart failure had a similar prognosis over
four years of follow-up. Cowie et al. (8), in Hillingdon, UK,
used a stricter definition of HF that included both a clinical
scoring system and objective evidence of cardiac dysfunc-
tion. This study of 220 patients with newly diagnosed HF
failed to find an association between the severity of LV
systolic dysfunction and survival. In Canada, McAlister et
al. (9) found 22% of their 562 patients with congestive heart
failure (CHF) to have normal systolic function. One-year
mortality did not differ from the group with systolic dys-
function. Studies conducted on elderly patients with CHF
found a high prevalence of normal systolic function and
similar prognosis for both systolic dysfunction and normal
systolic function (10,11). Observational studies of patients
discharged from hospital with a diagnosis of HF suggest
that short-term mortality may be lower in patients with
preserved LV systolic dysfunction, but long-term mortality
appears similar (12,13).
Patients who carry a diagnostic label of DHF also have
rates of recurrent hospitalization as high as those of patients
with HF and LV systolic dysfunction (9,12). These data
suggest that DHF may be a real and important entity, albeit
poorly defined.
The above studies and others have demonstrated that HF
is primarily a disease of the elderly. Older patients with HF
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are more likely to be women and more likely to have
preserved systolic function (14). These observations could
have major implications for the future, due to the aging of
the population (15,16).
PROBLEMS WITH THE DEFINITION OF DHF
Currently, a diagnosis of DHF is often made as a result of
a patient presenting with symptoms and signs suggestive of
HF in whom LV systolic dysfunction is subsequently
excluded. This is unsatisfactory for several reasons. Patients
without any cardiac abnormality could be labeled as HF.
Studies show considerable differences between clinicians in
eliciting the symptoms and signs of HF, making a diagnosis
based on these criteria alone unreliable (17). Many patients
with HF symptoms and preserved LV systolic function have
alternative explanations for their symptoms. Also, LV sys-
tolic dysfunction could be transient. This has led some to
question the validity of a diagnosis of HF in the presence of
preserved systolic function.
Recently, Caruana et al. (18) suggested that most patients
with symptoms suggestive of HF but preserved systolic
function had alternative, often noncardiological reasons for
their symptoms, including pulmonary disease, obesity and
myocardial ischemia. They suggested that DHF was more
often a misdiagnosis than a true entity. However, they did
not attempt to determine the predominant pathology for the
patients’ symptoms, but rather simply described competing
diagnoses. No adequate investigation was attempted with
which to refute diastolic dysfunction as a cause of symp-
toms.
The gold standard for defining diastolic dysfunction is
left heart catheterization and evaluation of pressure-volume
curves at rest and during exercise (19). However, this is not
feasible as an investigative tool for the majority of patients.
Echocardiography, although widely available, has consider-
able limitations. Current European guidelines on the echo-
cardiographic diagnosis of DHF are unsatisfactory because
of their complexity, their lack of applicability to patients
with atrial fibrillation and the lack of data demonstrating
their accuracy (20,21). Atrial fibrillation is common in the
population of interest. Techniques for the noninvasive
measurement of LV filling pressures are not widely dissem-
inated or validated.
In an attempt to overcome some of these problems, Vasan
et al. (21) recently put forward criteria for DHF and allowed
for diagnostic uncertainty according to a hierarchy of
evidence. Using their criteria, DHF is definitely present if a
patient meets the following three conditions in hierarchical
fashion: 1) definite evidence of HF, 2) objective evidence of
normal LV systolic function in proximity to the HF event,
and 3) objective evidence of LV diastolic dysfunction on
cardiac catheterization. If the first two criteria are satisfied
but information on the third is lacking, probable DHF is
present. Possible DHF is present when there is less diag-
nostic certainty with the first criterion being satisfied, the
second criterion partially satisfied (e.g., ejection fraction
[EF] not measured in proximity to the HF event) and the
third criterion is lacking. This classification accepts diag-
nostic uncertainty, which is a useful starting point but
means that few patients will receive a definite diagnosis of
DHF.
A recent report of patients with acute cardiogenic pul-
monary edema and hypertension showed a low prevalence of
LV systolic dysfunction during the acute episode and on
subsequent follow-up, suggesting that transient LV systolic
dysfunction is not a common entity, at least in this group of
patients (22).
THERAPY FOR DHF
Although many treatments may improve diastolic function
in patients with HF secondary to LV systolic dysfunction,
there is remarkably little evidence that any treatment is of
benefit, symptomatic or prognostic, in patients with DHF.
Diuretics should be effective in controlling fluid retention.
Subgroup data (n 218) from the V-HeFT trials suggested
that angiotensin-converting enzyme (ACE) inhibitors re-
duced mortality even in patients with relatively well-
preserved LV systolic dysfunction (23), but a similar group
of patients in the CONSENSUS study (n  57) did not
appear to benefit (24). One small study of enalapril (25) and
another small study using verapamil (26) have demonstrated
benefit. Losartan has been shown to improve diastolic
dysfunction and exercise tolerance in patients with a hyper-
tensive response to exercise (27). Aronow et al. in 1997 (28)
showed that propranolol reduced mortality over 32 months
in a study of 158 older (62 years) patients with prior
myocardial infarction (MI), preserved ventricular function
and HF. Propranolol induced a further increase in LV EF
and a reduction in LV mass. The DIG (Digitalis Investi-
gation Group) trial (29) included an ancillary study that
examined the effects of digoxin in patients with HF and
relatively preserved LV systolic function (EF  45%). As
with the main trial, the results in the ancillary study of 988
patients showed no mortality benefit of digoxin, but both
the overall rates of hospitalization and worsening heart
failure were significantly reduced.
Definition, diagnosis and treatment are integrally linked.
Lack of a proper definition of DHF may lead to a failure to
show benefit in a randomized controlled outcome study
even with an effective intervention, because the wrong
patients were recruited. Practical clinical entry criteria em-
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ployed in a study with a positive outcome will help shape the
future definition of DHF.
ONGOING TRIALS
Currently, four large outcome studies are investigating the
role of ACE inhibitors, angiotensin receptor blockers and
beta-blockers in patients with DHF or HF with preserved
LV systolic function (30,31) (Table 1). The PEP-CHF
(Perindopril in Elderly People with Chronic Heart Failure)
(30) is enrolling patients with echocardiographic evidence of
diastolic dysfunction and randomizing them to placebo and
perindopril. Two placebo-controlled studies of angiotensin
II receptor antagonists, the CHARM (Candesartan in
Heart failure–Assessment of Reduction in Mortality and
morbidity) (31) and the I-PRESERVE (Irbesartan in Heart
Failure with Preserved Systolic Function) trials, enroll
patients with clinical features suggestive of HF and then
exclude those with impaired LV systolic function. The
SENIORS (Study of Effects of Nebivolol Intervention on
Outcomes and Rehospitalization in Seniors with heart
failure), a placebo-controlled trial of nebivolol, adopts a
similar strategy of diagnosis. Two smaller trials use Doppler
echocardiographic criteria to identify patients with DHF
(32,33) (Table 1). It is likely that other, smaller mechanistic
and large outcome trials are being planned. Further details
are shown in Table 1.
It is likely that many patients in the CHARM,
I-PRESERVE and SENIORS trials will not have DHF
due to the strategy of making a diagnosis by exclusion. Some
patients in these trials will not have normal cardiac function.
However, retrospective analyses should be able to identify,
by clinical, echocardiographic and biochemical means, sub-
sets of patients with a high cardiovascular morbidity and
mortality related to HF. These analyses should give diag-
nostic insights into DHF. The PEP–CHF trial has positive
diagnostic criteria for DHF, and should the trial show a
benefit, its entry criteria might constitute the first practical
definition of at least one group of patients with DHF.
When the results of these trials are known, physicians
should be in a better position not only to define DHF but
also to manage it, because information will at last be
available on what to give and what to withhold.
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